RESISTENTIA PHARMACEUTICALS
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
RESISTENTIA PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
1998-01-01
Address:
Uppsala, Uppsala Lan, Sweden
Country:
Sweden
Status:
Active
Total Funding:
13.96 M USD
Similar Organizations
Epicyte Pharmaceuticals
Epicyte Pharmaceutical is focused on development therapeutic monoclonal antibodies for cancer, infectious and inflammatory diseases.
Investors List
Innovations Kapital
Innovations Kapital investment in Series C - Resistentia Pharmaceuticals
Industrifonden
Industrifonden investment in Series C - Resistentia Pharmaceuticals
GSK
GSK investment in Series C - Resistentia Pharmaceuticals
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series C - Resistentia Pharmaceuticals
HealthCap
HealthCap investment in Series C - Resistentia Pharmaceuticals